ISRCTN89514817已完成3 期
A phase III, double-blind, placebo-controlled trial and long term safety extension of obeticholic acid in patients with primary biliary cirrhosis
Intercept Pharmaceuticals Inc. (USA)0 个研究点目标入组 217 人开始时间: 2012年2月24日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 217
研究概览
简要总结
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27532829
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Definite or probable PBC diagnosis (consistent with AASLD and EASL Practice Guidelines, as demonstrated by the presence of = 2 of the following 3 diagnostic factors:
- •1.1. History of elevated Alkaline phosphatase (ALP) levels for at least 6 months prior to Day 0
- •1.2. Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)
- •1.3. Liver biopsy consistent with PBC
- •2. At least 1 of the following qualifying biochemistry values:
- •2.1. ALP = 1.67x upper limit of normal (ULN)
- •2.2. Total bilirubin > ULN but < 2x ULN
- •3. Age = 18 years
- •4. Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for = 3 months) prior to Day 0, or unable to tolerate UDCA (no UDCA for = 3 months) prior to Day 0
- •5. Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use = 1 effective (= 1% failure rate) method of contraception during the trial and until the EOT visit. Effective methods of contraception are considered to be:
- •5.1. Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or
- •5.2. Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or
- •5.3. Intrauterine device (IUD)
- •5.4. Vasectomy (partner)
- •6. Must provide written informed consent and agree to comply with the trial protocol
排除标准
- •1. History or presence of other concomitant liver diseases including:
- •1.1. Hepatitis B or C virus (HCV, HBV) infection
- •1.2. Primary sclerosing cholangitis (PSC)
- •1.3. Alcoholic liver disease
- •1.4. Definite autoimmune liver disease or overlap hepatitis
- •1.5. Nonalcoholic steatohepatitis (NASH)
- •1.6. Gilbert?s Syndrome (due to interpretability of bilirubin levels)
- •2. Presence of clinical complications of PBC or clinically significant hepatic decompensation, including:
- •2.1. History of liver transplantation, current placement on a liver transplant list or current Model for End-Stage Liver Disease (MELD) score = 15
- •2.2. Portal hypertension and complications, including: known esophageal varices, poorly controlled or diuretic resistant ascites, history of variceal bleeds or related interventions (e.g., insertion of variceal bands or transjugular intrahepatic portosystemic shunts [TIPS]), hepatic encephalopathy
- •2.3. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2x ULN
- •2.4. Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178 µmol/L)
- •3. Patients with a history of severe pruritus requiring current or prior systemic treatment [e.g., with bile acid sequestrants (BAS) or rifampicin]
- •4. Administration of the following medications is prohibited as specified below:
- •4.1. Prohibited 6 months prior to Day 0 and throughout the trial (i.e., to last dose to last dose and/or EOT): azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide and other systemic corticosteroids; potentially hepatotoxic drugs (including a-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
- •4.2. Prohibited 12 months prior to Day 0 and throughout the trial (i.e., to last dose to last dose and/or EOT): antibodies or immunotherapy directed against interleukins or other cytokines or chemokines
- •5. Patients who have previously participated in a clinical trial of OCA will not be allowed to participate
- •6. History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pretreatment) QT or QTc interval of > 500 msec
- •7. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
- •8. Known history of human immunodeficiency virus (HIV) infection
- •9. History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine (e.g., inflammatory bowel disease or gastric bypass procedures; [gastric lap band is acceptable])
- •10. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease) or which may diminish life expectancy to < 2 years, including known cancers (except carcinomas in situ or other stable, relatively benign conditions such as chronic lymphatic leukemia)
- •11. Other clinically significant medical conditions that are not well controlled or for which medication needs are anticipated to change
研究者
相似试验
已完成
不适用
Theophylline With Inhaled CorticoSteroid (ICS)Topic: Primary Care Research Network for England, RespiratorySubtopic: Not Assigned, Respiratory (all Subtopics)Disease: Respiratory, All DiseasesRespiratoryChronic obstructive pulmonary disease, unspecifiedISRCTN27066620niversity of Aberdeen (UK)1,578
已完成
3 期
Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)Mental and Behavioural DisordersSchizophreniaISRCTN64695913Dainippon Sumitomo Pharma America Inc. (USA)480
已完成
不适用
A randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of intracoronary NITRITE infusion during Acute Myocardial InfarctioTopic: CardiovascularSubtopic: Cardiovascular (all Subtopics)Disease: AtherothrombosisCirculatory SystemAcute myocardial infarctionISRCTN38736987Barts and The London NHS Trust (UK)80
已完成
2 期
Repeated application of gene therapy in cystic fibrosis patientsNutritional, Metabolic, EndocrineCystic fibrosisISRCTN71164341Imperial College London (UK)130
已完成
3 期
Gemcitabine and Docetaxel versus Doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue SarcomasCancerISRCTN07742377niversity College London (UCL) (UK)250